Global Duchenne Muscular Dystrophy Market Growth 2025-2031

Global Duchenne Muscular Dystrophy Market Growth 2025-2031

The global Duchenne Muscular Dystrophy market size is predicted to grow from US$ 2218 million in 2025 to US$ 19500 million in 2031; it is expected to grow at a CAGR of 43.7% from 2025 to 2031.

uchenne muscular dystrophy is an x-linked genetic disorder that affects mostly boys. In Duchenne, boys begin to show signs of muscle weakness as early as two to five years of age. The disease gradually weakens the skeletal or voluntary muscles in the arms, legs and trunk. Due to progressive muscle weakness, Duchenne patients are often wheelchair bound between the ages of seven and 13 years old. At a later stage, the boys" respiratory and cardiac muscles are also affected and for most boys, respiratory and cardiac failure are major causes of death, often prevalent by the age of 20.

Global Duchenne Muscular Dystrophy key players include Sarepta Therapeutics, PTC Therapeutics, etc.

North America is the largest market, with a share over 70%, followed by Europe, and Japan, both have a share over 25 percent.

In terms of product, Exondys 51 is the largest segment, with a share over 55%. And in terms of application, the largest application is Hospitals, followed by Clinics, Home Care, etc.

LP Information, Inc. (LPI) ' newest research report, the “Duchenne Muscular Dystrophy Industry Forecast” looks at past sales and reviews total world Duchenne Muscular Dystrophy sales in 2024, providing a comprehensive analysis by region and market sector of projected Duchenne Muscular Dystrophy sales for 2025 through 2031. With Duchenne Muscular Dystrophy sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Duchenne Muscular Dystrophy industry.

This Insight Report provides a comprehensive analysis of the global Duchenne Muscular Dystrophy landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Duchenne Muscular Dystrophy portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Duchenne Muscular Dystrophy market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Duchenne Muscular Dystrophy and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Duchenne Muscular Dystrophy.

This report presents a comprehensive overview, market shares, and growth opportunities of Duchenne Muscular Dystrophy market by product type, application, key manufacturers and key regions and countries.

Segmentation by Type:
Exondys 51
Emflaza
Translarna

Segmentation by Application:
Hospitals
Clinics
Home Care

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
Sarepta Therapeutics
PTC Therapeutics
Pfizer
Bristol-Myers Squibb
Italfarmaco
Santhera Pharmaceuticals

Key Questions Addressed in this Report

What is the 10-year outlook for the global Duchenne Muscular Dystrophy market?

What factors are driving Duchenne Muscular Dystrophy market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Duchenne Muscular Dystrophy market opportunities vary by end market size?

How does Duchenne Muscular Dystrophy break out by Type, by Application?

Please note: The report will take approximately 2 business days to prepare and deliver.